Followers | 198 |
Posts | 14014 |
Boards Moderated | 0 |
Alias Born | 04/03/2007 |
Tuesday, February 27, 2024 8:21:36 AM
It's clear that this represents a large unmet medical need.
— Virios Therapeutics (@ViriosBiotech) February 27, 2024
Millions of Americans suffer from long COVID. Why do treatments remain out of reach? https://t.co/kCYE7QImFB via @usatoday
Recent VIRI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2024 01:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 01:25:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2024 08:30:26 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 10/15/2024 08:19:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/07/2024 12:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:02:34 PM
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) • GlobeNewswire Inc. • 10/07/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 02:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:30:13 PM
- Virios Therapeutics Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 01:15:00 PM
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 01:41:56 PM
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center • GlobeNewswire Inc. • 07/23/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 01:15:20 PM
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/22/2024 05:30:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/20/2024 08:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:28:00 PM
- Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/20/2024 12:53:09 AM
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/17/2024 08:10:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/17/2024 08:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 02:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:01:31 PM
- Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:45:00 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM